Abrdn Healthcare Investors (NYSE: HQH) is a Financial Services company in the Asset Management industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 12.14 | EPS (ttm) | 1.84 | Insider Own | 0.37% | Shs Outstand | 57.19M | Perf Week | 2.29% |
| Market Cap | 1.28B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.24% | Shs Float | 57.19M | Perf Month | 1.55% |
| Enterprise Value | 1.28B | PEG | 0.08 | EPS next Q | - | Inst Own | - | Short Float | 0.21% | Perf Quarter | 12.09% |
| Income | 99.00M | P/S | 12.78 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.74 | Perf Half Y | 15.57% |
| Sales | 100.00M | P/B | 1.17 | EPS next Y | - | ROA | 8.99% | Short Interest | 122.81K | Perf YTD | 17.95% |
| Book/sh | 19.13 | P/C | 0.00 | EPS next 5Y | - | ROE | 9.16% | 52W High | 22.69 -1.54% | Perf Year | 41.93% |
| Cash/sh | 0.00 | P/FCF | 0.00 | EPS past 3/5Y | - -19.67% | ROIC | 9.00% | 52W Low | 15.51 44.04% | Perf 3Y | 30.34% |
| Dividend Est. | 2.44 (10.92%) | EV/EBITDA | 12.91 | Sales past 3/5Y | 132.08% 61.86% | Gross Margin | - | Volatility | 1.99% 2.19% | Perf 5Y | -12.15% |
| Dividend TTM | 2.32 (10.38%) | EV/Sales | 12.78 | EPS Y/Y TTM | - | Oper. Margin | 98.80% | ATR (14) | 0.46 | Perf 10Y | -11.28% |
| Dividend Ex-Date | May 21, 2026 | Quick Ratio | 2.15 | Sales Y/Y TTM | - | Profit Margin | 98.80% | RSI (14) | 68.13 | Recom | - |
| Dividend Gr. 3/5Y | 8.60% 2.88% | Current Ratio | 2.15 | EPS Q/Q | - | SMA20 | 3.94% | Beta | 0.72 | Target Price | - |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 183.33% | SMA50 | 7.99% | Rel Volume | 1.12 | Prev Close | 22.14 |
| Employees | - | LT Debt/Eq | - | Earnings | - | SMA200 | 14.71% | Avg Volume | 202.38K | Price | 22.34 |
| IPO Date | Apr 23, 1987 | Option/Short | Yes / Yes | EPS/Sales Surpr. | - | Net Debt/EBITDA | 0.00 | Volume | 225,716 | Change | 0.90% |
Abrdn Healthcare Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the healthcare sector, including the biotechnology, medical devices, and pharmaceuticals industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as current or anticipated market position for services or products, experienced business management, recognized technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index, the S&P 500 Index, and the S&P 1500 Healthcare Index. Abrdn Healthcare Investors was formed on October 31, 1986 and is domiciled in the United States.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 100 | 11 | 10 | 8 | 6 | 9 | 8 | 7 | 6 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 100 | 11 | 10 | 8 | 6 | 9 | 8 | 7 | 6 | |
| Selling, General and Administrative Excl. Other | 1 | 11 | 11 | 12 | 13 | 11 | 10 | 11 | 11 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | 99 | 0 | -1 | -4 | -6 | -2 | -3 | -4 | -5 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 0 | 185 | 58 | -191 | 161 | 243 | -142 | 73 | 126 | |
| Net Income Before Taxes | 99 | 185 | 56 | -194 | 155 | 241 | -145 | 69 | 121 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | 99 | 185 | 56 | -194 | 155 | 241 | -145 | 69 | 121 | |
| Net Income From Continuing Operations | 99 | 185 | 56 | -194 | 155 | 241 | -145 | 69 | 121 | |
| Net Income | 99 | 185 | 56 | -194 | 155 | 241 | -145 | 69 | 121 | |
| EPS (Recurring) | 1.84 | 3.55 | 1.14 | -4.10 | 3.49 | 5.50 | -3.39 | 1.64 | 2.98 | |
| EPS (Basic, Before Extraordinaries) | 1.84 | 3.55 | 1.14 | -4.10 | 3.49 | 5.50 | -3.39 | 1.64 | 2.98 | |
| EPS (Diluted) | 1.84 | 3.55 | 1.14 | -4.10 | 3.49 | 5.50 | -3.39 | 1.64 | 2.98 | |
| EBITDA | 99 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 10.29 | 4.52 | 14.54 | — | 6.81 | 4.33 | — | 10.95 | 7.57 | |
| Price To Sales Ratio | 10.23 | 75.87 | 81.19 | 105.75 | 178.20 | 116.50 | 112.23 | 107.70 | 154.09 | |
| Gross Margin | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Operating Margin | 99.00 | 0.00 | -10.00 | -50.00 | -100.00 | -22.22 | -37.50 | -57.14 | -83.33 | |
| Net Margin | 99.00 | 1,681.82 | 560.00 | -2,425.00 | 2,583.33 | 2,677.78 | -1,812.50 | 985.71 | 2,016.67 | |
| Shares Outstanding | 54 | 52 | 49 | 47 | 45 | 44 | 43 | 42 | 41 | |
| Market Capitalization | 1,023 | 835 | 812 | 846 | 1,069 | 1,049 | 898 | 754 | 925 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mahai Chris LaVictoire | Director | Jul 16 '26 | Buy | 20.96 | 501 | 10,501 | 501 | Jul 20 |
| DiMartino Rose | Director | Jul 16 '24 | Buy | 18.88 | 1,000 | 18,880 | 1,000 | Jul 18 |
| Goetz Kathleen | Director | Apr 09 '24 | Buy | 16.42 | 525 | 8,622 | 1,080 | Apr 12 |
| Goodson Alan R | Vice President | Dec 21 '23 | Buy | 16.13 | 170 | 2,742 | 170 | Jan 09 |
| Reit Todd | Director | Jan 02 '24 | Buy | 16.93 | 1,000 | 16,929 | 1,000 | Jan 04 |
| Maher Bill | Director | Dec 28 '23 | Buy | 16.58 | 1,000 | 16,580 | 1,000 | Jan 02 |
| OMSTEAD DANIEL R | President | Sep 25 '23 | Buy | 15.63 | 9,500 | 148,515 | 178,269 | Sep 25 |
| OMSTEAD DANIEL R | President | Sep 20 '23 | Buy | 15.88 | 9,500 | 150,829 | 168,769 | Sep 20 |
| Goetz Kathleen | director: | Mar 23 '22 | Buy | 20.42 | 74 | 1,501 | 555 | Mar 24 |
| Goetz Kathleen | Director | Jan 26 '22 | Buy | 21.52 | 481 | 10,349 | 481 | Jan 27 |
| OMSTEAD DANIEL R | President | Oct 26 '20 | Buy | 20.53 | 5,200 | 106,744 | 125,411 | Oct 26 |
| OMSTEAD DANIEL R | President | Oct 21 '20 | Buy | 20.68 | 5,050 | 104,427 | 120,211 | Oct 21 |
| Bailey Jeffrey Allen | Director | Sep 23 '20 | Buy | 20.39 | 490 | 9,991 | 490 | Sep 23 |
| OMSTEAD DANIEL R | President | May 21 '20 | Buy | 21.01 | 5,000 | 105,054 | 110,357 | May 22 |
| OMSTEAD DANIEL R | President | Mar 17 '20 | Buy | 16.24 | 6,800 | 110,412 | 102,319 | Mar 17 |